OCULAR THERAPEUTIX INC (OCUL) Institutional Ownership Changes & 13F Activity
OCULAR THERAPEUTIX INC (OCUL). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q4 2025). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Fmr Llc, Avoro Capital Advisors Llc, Venrock Adviser, Llc, Tcg Crossover Management, Llc, and Adage Capital Partners Gp, L.L.C..
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Catalio Capital Management, Lp | Buy | +714,501 | — | 714,501 | $8.67M | Q4 2025 | Sep 02, 2026 |
| Algert Global Llc | Buy | +127,410 | — | 127,410 | $1.55M | Q4 2025 | Aug 11, 2026 |
| Seven Fleet Capital Management Lp | Buy | +17,100 | — | 17,100 | $207.59K | Q4 2025 | Feb 26, 2026 |
| Td Capital Management Llc | Buy | +47 | — | 47 | $571.00 | Q4 2025 | Feb 26, 2026 |
| Virtu Financial Llc | Buy | +65,627 | — | 65,627 | $797.00K | Q4 2025 | Feb 23, 2026 |
| Corient Private Wealth Llc | Buy | +30,215 | — | 30,215 | $366.81K | Q4 2025 | Feb 19, 2026 |
| Raymond James Financial Inc | Buy | +842,187 | — | 842,187 | $10.22M | Q4 2025 | Feb 18, 2026 |
| Mackenzie Financial Corp | Buy | +10,903 | — | 10,903 | $132.75K | Q4 2025 | Feb 18, 2026 |
| Newedge Advisors, Llc | Buy | +1,000 | — | 1,000 | $12.14K | Q4 2025 | Feb 18, 2026 |
| Fmr Llc | Buy | +31,785,605 | — | 31,785,605 | $385.88M | Q4 2025 | Feb 17, 2026 |
| Avoro Capital Advisors Llc | Buy | +10,777,777 | — | 10,777,777 | $130.84M | Q4 2025 | Feb 17, 2026 |
| Venrock Adviser, Llc | Buy | +7,315,547 | — | 7,315,547 | $88.81M | Q4 2025 | Feb 17, 2026 |
| Tcg Crossover Management, Llc | Buy | +5,740,231 | — | 5,740,231 | $69.69M | Q4 2025 | Feb 17, 2026 |
| Adage Capital Partners Gp, L.L.C. | Buy | +4,625,050 | — | 4,625,050 | $56.15M | Q4 2025 | Feb 17, 2026 |
| Alliancebernstein L.P. | Buy | +4,341,951 | — | 4,341,951 | $52.71M | Q4 2025 | Feb 17, 2026 |
| Janus Henderson Group Plc | Buy | +4,229,202 | — | 4,229,202 | $51.32M | Q4 2025 | Feb 17, 2026 |
| Logos Global Management Lp | Buy | +3,500,000 | — | 3,500,000 | $42.49M | Q4 2025 | Feb 17, 2026 |
| Millennium Management Llc | Buy | +3,207,881 | — | 3,207,881 | $38.94M | Q4 2025 | Feb 17, 2026 |
| Paradigm Biocapital Advisors Lp | Buy | +2,935,284 | — | 2,935,284 | $35.63M | Q4 2025 | Feb 17, 2026 |
| Octagon Capital Advisors Lp | Buy | +2,623,600 | — | 2,623,600 | $31.85M | Q4 2025 | Feb 17, 2026 |
| Citadel Advisors Llc | Buy | +2,475,849 | — | 2,475,849 | $30.06M | Q4 2025 | Feb 17, 2026 |
| Woodline Partners Lp | Buy | +1,666,136 | — | 1,666,136 | $20.23M | Q4 2025 | Feb 17, 2026 |
| Opaleye Management Inc. | Buy | +1,595,000 | — | 1,595,000 | $19.36M | Q4 2025 | Feb 17, 2026 |
| Saturn V Capital Management Lp | Buy | +1,504,880 | — | 1,504,880 | $18.27M | Q4 2025 | Feb 17, 2026 |
| Northern Trust Corp | Buy | +1,462,503 | — | 1,462,503 | $17.75M | Q4 2025 | Feb 17, 2026 |
| D. E. Shaw & Co., Inc. | Buy | +1,153,910 | — | 1,153,910 | $14.01M | Q4 2025 | Feb 17, 2026 |
| Artisan Partners Limited Partnership | Buy | +1,063,371 | — | 1,063,371 | $12.91M | Q4 2025 | Feb 17, 2026 |
| Acuta Capital Partners, Llc | Buy | +1,052,995 | — | 1,052,995 | $12.78M | Q4 2025 | Feb 17, 2026 |
| Point72 Asset Management, L.P. | Buy | +1,016,248 | — | 1,016,248 | $12.34M | Q4 2025 | Feb 17, 2026 |
| Voloridge Investment Management, Llc | Buy | +812,078 | — | 812,078 | $9.86M | Q4 2025 | Feb 17, 2026 |
Frequently asked questions about OCUL activity
Which institutional owners are buying OCUL?
Institutional owners buying OCUL include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in OCUL activity?
"Buy" means an investor increased their reported position in OCUL compared to the prior reporting period. This reflects growing exposure to OCULAR THERAPEUTIX INC (OCUL) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in OCUL increasing?
Institutional interest in OCUL can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related OCUL Institutional Insights
- OCUL Overview
- OCUL 13F Institutional Holders
- OCUL Superinvestors
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- OCUL Insider Trading & SEC Form 4 Activity
- OCUL Articles
- Top Institutional Investor Stock Rankings